Mental training program helps ease chemobrain in breast cancer
the ONA take:
A new program developed by UCLA researchers may ease post-treatment cognitive difficulties, better known as “chemo brain”, in patients with breast cancer, according to a study published in Psycho-Oncology.
In a randomized clinical trial, researchers led by Patricia Ganz, MD, built upon prior research that found a connection between neuro-psychological test performance and memory complaints in women being treated for early-stage breast cancer.
“We invited the women to participate in a research study that assigned them to early or delayed treatment with a five-week, two-hour group training session, where a psychologist taught them strategies to help them with their memory and maintaining their ability to pay attention to things,” Dr. Ganz said.
All the women who enrolled completed questions about their mood and mental functioning in follow-up testing.
Ganz and her fellow researchers found that women in the early intervention group reported improvements in memory complaints and test functioning, while those in the delayed group did not improve in either category.
“We hope that this might be an effective biologic way to assess the cognitive effects of cancer treatment in the future.”
A new program developed by UCLA researchers may ease post-treatment “chemo brain” in patients with breast cancer.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|